Pharmaceutical Cocrystal as a Viable Alternative to the Solid State Modification of Potential Drug Candidates: A Short Review

Authors

  • Dr. Tapas Kumar Adalder Assistant Professor (Stage II), Department of Chemistry (UG & PG), Jhargram Raj College, Jhargram-721507 (W.B.), India Author

DOI:

https://doi.org/10.31305/rrijm2024.v04.n03.007

Keywords:

Active Pharmaceutical ingredients, Polymorphic crystal, Crystal Engineering, Cocrystal, Supramolecular synthon, Cambridge Structural Database (CSD)

Abstract

Majority of the active pharmaceutical ingredients (APIs) are marketed as solid and solubility and bioavailability etc. issues are also associated with the solid form of drug molecules. Thus, pharmaceutical inductries developed some techniques namely selection better polymorph, salt selection with biologically acceptable components. Polymorphic crystals of APIs and salt selection for non-ionisable APIs are very difficult to achieve. Crystal Engineering based cocrystallisation of APIs have been developed to address some of the issues related to the solid form of APIs. This short review highlights the recent achievement of the pharmaceutical cocrystal with improved physico-chemical properties.

References

Wöhler, F. Annalen Chem. Pharm. 1844, 51, 145. DOI: https://doi.org/10.1002/jlac.18440510202

Almarsson, Ö.; Zaworotko, M. J. Chem. Commun. 2004, 1889-1896. DOI: https://doi.org/10.1039/b402150a

(a) Desiraju, G. R.; Vittal, J. J.; Ramanan, A. Crystal Engineering: A Text Book, IISc Press and World Scientific, India, 2011. (b) Desiraju, G. R. Crystal Engineering: The Design of Organic Solids, Elsevier, Amsterdam, 1989. (c) Desiraju, G. R. J. Chem. Sci. 2010, 122, 667-675. (d) Desiraju, G. R. Angew. Chem. Int. Ed. 2007, 46, 8342-8356

Goud, N. R.; Babu, N. J.; Nangia, A. Cryst. Growth Des. 2011, 11, 1930-1939. DOI: https://doi.org/10.1021/cg200094x

(a) Trask, A. V.; Motherwell, W. D. S.; Jones, W. Cryst. Growth Des. 2005, 5, 1013-1021. (b) Trask, A. V.; Motherwell, W. D. S.; Jones, W. Int. J. Pharm. 2006, 320, 114-123.

Remenar, J. F.; Morissette, S. L.; Peterson, M. L.; Moulton, B.; MacPhee, J.; Guzmán, H. R.; Almarsson, Ö. J. Am. Chem. Soc. 2003, 125, 8456-8457. DOI: https://doi.org/10.1021/ja035776p

Childs, S. L.; Chyall, L. J.; Dunlap, J. T.; Smolenskaya, V. N.; Stahly, B. C.; Stahly, G. P. J. Am. Chem. Soc. 2004, 126, 13335-13342. DOI: https://doi.org/10.1021/ja048114o

Fleischman, S. G.; Kuduva, S. S.; McMahon, J. A.; Moulton, B.; Walsh, R. D. B.; Rodríguez-Hornedo, N.; Zaworotko, M. J. Cryst. Growth Des. 2003, 3, 909-919. DOI: https://doi.org/10.1021/cg034035x

Downloads

Published

2024-09-30

How to Cite

Adalder, T. K. (2024). Pharmaceutical Cocrystal as a Viable Alternative to the Solid State Modification of Potential Drug Candidates: A Short Review. Revista Review Index Journal of Multidisciplinary, 4(3), 56-60. https://doi.org/10.31305/rrijm2024.v04.n03.007